UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000016362
Receipt No. R000018999
Official scientific title of the study Effects of OTC switching on prescription trends of ethical drugs
Date of disclosure of the study information 2015/01/30
Last modified on 2018/06/18 (Ver. 7)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Effects of OTC switching on prescription trends of ethical drugs
Title of the study (Brief title) Effects of OTC switching on prescription drugs
Region
Japan

Condition
Condition Hay fever, Hyperlipidemia, Pain
Classification by specialty
Medicine in general
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Investigate the effects of OTC switching on prescription trends of original ethical drugs using a nation-wide pharmacy claims database.
Basic objectives2 Others
Basic objectives -Others Drug utilization
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Regional, monthly trends in prescription and prescribed patients before and after OTC switching.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients despensed with the study prescription drugs
Key exclusion criteria Not applicable
Target sample size 100000

Research contact person
Name of lead principal investigator Hisashi Urushihara
Organization Keio University, Faculty of Pharmacy
Division name Drug Dev. Regulartory Sci,
Address 1-5-30, Shiba-koen, Minato-ku, TOKYO, JAPAN
TEL +81354002649
Email urushihara-hs@pha.keio.ac.jp

Public contact
Name of contact person Keio University
Organization Keio University, Faculty of Pharmacy
Division name Drug Dev. Regulartory Sci,
Address 1-5-30, Shiba-koen, Minato-ku, TOKYO, JAPAN
TEL +81354002649
Homepage URL
Email urushihara-hs@pha.keio.ac.jp

Sponsor
Institute Keio University
Institute
Department

Funding Source
Organization Keio University
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 01 Month 30 Day

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 01 Month 07 Day
Anticipated trial start date
2015 Year 01 Month 20 Day
Last follow-up date
2016 Year 12 Month 31 Day
Date of closure to data entry
2016 Year 12 Month 31 Day
Date trial data considered complete
2017 Year 03 Month 31 Day
Date analysis concluded
2018 Year 12 Month 31 Day

Related information
URL releasing protocol
Publication of results Partially published
URL releasing results
Results Manuscript have been developed and publication process ongoing.
Other related information Drug utilization study using a commercial pharmacy claims database run by IMS Japan, which consists of pharmacy claims data accumulating 53 million prescriptions annually from more than 3000 dispensing pharmacies out-of-hospital beginning from January 2008, accounting for 6.9% of the total national prescriptions.

The study ethical drugs are selected as ones whose OTC-switched drugs started to be sold within the study period and allowing sufficient pre-switching period for evaluating trend changes, including troxipide, loxoprofen sodium hydrate, mequitazine, epinastine hydrochloride, pemirolast, fexofenadine hydrochloride, cetirizine hydrochloride, and ethyl icosapentate.

Management information
Registered date
2015 Year 01 Month 28 Day
Last modified on
2018 Year 06 Month 18 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018999